[1] Prashanth R, Tagore S, Vinaya G.Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors[J]. World J Oncol,2019, 10(1):10-27. [2] Gravina GL, Senapedis W, Mccauley D, et al.Nucleo-cytoplasmic transport as a therapeutic target of cancer[J]. J Hematol Oncol,2014,7:85. [3] Gupta A, Saltarski JM, White MA, et al.Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer[J]. J Thorac Oncol,2017,12(9):1446-1450. [4] Chen Y, Camacho SC, Silvers TR, et al.Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer[J]. Clin Cancer Res,2017,23(6):1552-1563. [5] Jain P, Kanagal-Shamanna R, Wierda W, et al.Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia[J]. Am J Hematol,2016,91(11):E478-E479. [6] Duijvesz D, Burnum-Johnson KE, Gritsenko MA, et al.Proteomic profiling of exosomes leads to the dentification of novel biomarkers for prostate cancer[J]. PLoS One,2013,8(12):e82589. [7] American Association for cancer research.XPO1 Inhibitor Approved for Multiple Myeloma[J]. Cancer Discov,2019,9(9):1150-1151. [8] Birnbaum DJ, Finetti P, Birnbaum D, et al.XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma[J]. J Clin Med,2019,8(5): 596. [9] Akagi I, Okayama H, Schetter A J, et al.Combination of Protein Coding and Noncoding Gene Expression as a Robust Prognostic Classifier in Stage I Lung Adenocarcinoma[J]. Cancer Res,2013,73(13):3821-3832. [10] Huang W, Yue L, Qiu W, et al.Prognostic value of CRM1in pancreas cancer[J]. Clin Invest Med,2009,32(6): E315. [11] 李苑华,庄燕妍,黄娴娴,等. XPO1抑制剂KPT-330对人胰腺癌细胞株MIA PaCa-2增殖和凋亡的影响[J]. 胃肠病学,2018,23(11):658-663. [12] Kutay U, Güttinger S.Leucine-rich nuclear-export signals: born to be weak[J]. Trends Cell Biol, 2005, 15(3):121-124. [13] Wang AY, Liu H.The past, present, and future of CRM1/XPO1 inhibitors[J]. Stem Cell Investig,2019,6:6. [14] Lapalombella R, Sun Q, Williams K, et al.Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia[J]. Blood,2012,120(23):4621-4634. [15] Khan SH.Genome-Editing Technologies: Concept, Pros, and Cons of Various Genome-Editing Techniques and Bioethical Concerns for Clinical Application[J]. Mol Ther Nucleic Acids,2019,16:326-334. |